| # | Title | Journal | Year | Citations |
|---|
| 1 | Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study | Cardiovascular Drugs and Therapy | 2005 | 1,039 |
| 2 | Anthracycline Chemotherapy and Cardiotoxicity | Cardiovascular Drugs and Therapy | 2017 | 654 |
| 3 | Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival--4 | Cardiovascular Drugs and Therapy | 1997 | 451 |
| 4 | Elastic properties and Windkessel function of the human aorta | Cardiovascular Drugs and Therapy | 1995 | 333 |
| 5 | Phospholipase A2 Biochemistry | Cardiovascular Drugs and Therapy | 2009 | 332 |
| 6 | The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study | Cardiovascular Drugs and Therapy | 2001 | 306 |
| 7 | Necrostatin: A Potentially Novel Cardioprotective Agent? | Cardiovascular Drugs and Therapy | 2007 | 292 |
| 8 | SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor | Cardiovascular Drugs and Therapy | 2017 | 281 |
| 9 | Oxygen-derived free radicals and myocardial reperfusion injury: An overview | Cardiovascular Drugs and Therapy | 1991 | 258 |
| 10 | Oxidized LDL, LOX-1 and Atherosclerosis | Cardiovascular Drugs and Therapy | 2011 | 247 |
| 11 | Nicotine and sympathetic neurotransmission | Cardiovascular Drugs and Therapy | 1997 | 225 |
| 12 | Grape Resveratrol Increases Serum Adiponectin and Downregulates Inflammatory Genes in Peripheral Blood Mononuclear Cells: A Triple-Blind, Placebo-Controlled, One-Year Clinical Trial in Patients with Stable Coronary Artery Disease | Cardiovascular Drugs and Therapy | 2013 | 197 |
| 13 | ?Escape? of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy | Cardiovascular Drugs and Therapy | 1995 | 189 |
| 14 | Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure | Cardiovascular Drugs and Therapy | 2020 | 188 |
| 15 | Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2) | Cardiovascular Drugs and Therapy | 2009 | 183 |
| 16 | A Single Bolus of a Long-acting Erythropoietin Analogue Darbepoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study | Cardiovascular Drugs and Therapy | 2006 | 176 |
| 17 | Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases | Cardiovascular Drugs and Therapy | 2016 | 165 |
| 18 | Comparison of trimetazidine with nifedipine in effort angina: A double-blind, crossover study | Cardiovascular Drugs and Therapy | 1990 | 164 |
| 19 | Intima media thickness as a surrogate marker for generalised atherosclerosis | Cardiovascular Drugs and Therapy | 2002 | 163 |
| 20 | Mechanism of Cardioprotection by Early Ischemic Preconditioning | Cardiovascular Drugs and Therapy | 2010 | 161 |
| 21 | Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher | Cardiovascular Drugs and Therapy | 2016 | 160 |
| 22 | Cholesterol biosynthesis and metabolism | Cardiovascular Drugs and Therapy | 1992 | 154 |
| 23 | The Cardioprotective Effect of Necrostatin Requires the Cyclophilin-D Component of the Mitochondrial Permeability Transition Pore | Cardiovascular Drugs and Therapy | 2007 | 150 |
| 24 | Cardiac sarcoidosis: Diagnostic, prognostic, and therapeutic considerations | Cardiovascular Drugs and Therapy | 1996 | 148 |
| 25 | Hypolipidemic and antioxidant effects of commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia | Cardiovascular Drugs and Therapy | 1994 | 145 |
| 26 | Efficacy and Safety of Tolvaptan in Heart Failure Patients with Volume Overload Despite the Standard Treatment with Conventional Diuretics: A Phase III, Randomized, Double-blind, Placebo-controlled Study (QUEST Study) | Cardiovascular Drugs and Therapy | 2011 | 145 |
| 27 | The Interplay between Pro-Death and Pro-Survival Signaling Pathways in Myocardial Ischemia/Reperfusion Injury: Apoptosis Meets Autophagy | Cardiovascular Drugs and Therapy | 2006 | 140 |
| 28 | Diabetic Nephropathy: a Tangled Web to Unweave | Cardiovascular Drugs and Therapy | 2017 | 135 |
| 29 | Improvement in Endothelial Progenitor Cells from Peripheral Blood by Ramipril Therapy in Patients with Stable Coronary Artery Disease | Cardiovascular Drugs and Therapy | 2004 | 134 |
| 30 | Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit | Cardiovascular Drugs and Therapy | 2008 | 134 |
| 31 | The Second Window of Preconditioning (SWOP) Where Are We Now? | Cardiovascular Drugs and Therapy | 2010 | 133 |
| 32 | New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect? | Cardiovascular Drugs and Therapy | 2013 | 133 |
| 33 | Predictors of Adherence to Statins for Primary Prevention | Cardiovascular Drugs and Therapy | 2007 | 131 |
| 34 | The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs | Cardiovascular Drugs and Therapy | 1990 | 129 |
| 35 | Cardiovascular Drugs and Serum Uric Acid | Cardiovascular Drugs and Therapy | 2003 | 129 |
| 36 | Iron overload cardiomyopathies: New insights into an old disease | Cardiovascular Drugs and Therapy | 1994 | 128 |
| 37 | The Discovery of LOX-1, its Ligands and Clinical Significance | Cardiovascular Drugs and Therapy | 2011 | 126 |
| 38 | The Benefits of Early Combination Treatment of Carvedilol and an ACE-Inhibitor in Mild Heart Failure and Left Ventricular Systolic Dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN) | Cardiovascular Drugs and Therapy | 2004 | 123 |
| 39 | Role of MicroRNAs in Cardiac Remodeling and Heart Failure | Cardiovascular Drugs and Therapy | 2011 | 123 |
| 40 | Mechanisms of action of nitrates | Cardiovascular Drugs and Therapy | 1994 | 121 |
| 41 | Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial | Cardiovascular Drugs and Therapy | 1999 | 120 |
| 42 | Rosuvastatin Alleviates Diabetic Cardiomyopathy by Inhibiting NLRP3 Inflammasome and MAPK Pathways in a Type 2 Diabetes Rat Model | Cardiovascular Drugs and Therapy | 2014 | 120 |
| 43 | Pathophysiologic and therapeutic importance of tissue ACE: a consensus report | Cardiovascular Drugs and Therapy | 2002 | 118 |
| 44 | Metabolic Syndrome: Does it Differ Between Women and Men? | Cardiovascular Drugs and Therapy | 2015 | 116 |
| 45 | T-type Ca2+ channels and pharmacological blockade: potential pathophysiological relevance | Cardiovascular Drugs and Therapy | 1997 | 115 |
| 46 | The mammalian sinoatrial node | Cardiovascular Drugs and Therapy | 1988 | 113 |
| 47 | Diabetic cardiomyopathy | Cardiovascular Drugs and Therapy | 1994 | 113 |
| 48 | Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction | Cardiovascular Drugs and Therapy | 1998 | 112 |
| 49 | Internal pH, Na+, and Ca2+ regulation by trimetazidine during cardiac cell acidosis | Cardiovascular Drugs and Therapy | 1988 | 111 |
| 50 | Myocardial Ischaemia-reperfusion Injury is Attenuated by Intact Glucagon Like Peptide-1 (GLP-1) in the In Vitro Rat Heart and may Involve the p70s6K Pathway | Cardiovascular Drugs and Therapy | 2007 | 111 |
